Summary
The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends and leading companies.
- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $110.2 billion in 2016.The Mexico was the fastest growing country, with a CAGR of 13.7% over the 2012-16 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $99.7 billion in 2016. This was followed by Mexico and Canada, with a value of $6.3 and $4.2 billion, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $141.2 billion in 2021, followed by Mexico and Canada with expected values of $10.1 and $4.9 billion, respectively.
Scope
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to buy
- What was the size of the NAFTA generics market by value in 2016?
- What will be the size of the NAFTA generics market in 2021?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the NAFTA generics market?
'
Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
NAFTA Generics
Industry Outlook
Generics in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine
List of Tables
Table 1: NAFTA countries generics industry, revenue ($bn), 2012-21
Table 2: NAFTA countries generics industry, revenue ($bn), 2012-16
Table 3: NAFTA countries generics industry forecast, revenue ($bn), 2016-21
Table 4: Canada generics market value: $ billion, 2012–16
Table 5: Canada generics market volume: % of total pharma volume, 2012–16
Table 6: Canada generics market geography segmentation: $ billion, 2016
Table 7: Canada generics market value forecast: $ billion, 2016–21
Table 8: Canada generics market volume forecast: % of total pharma volume, 2016–21
Table 9: Canada size of population (million), 2012–16
Table 10: Canada gdp (constant 2005 prices, $ billion), 2012–16
Table 11: Canada gdp (current prices, $ billion), 2012–16
Table 12: Canada inflation, 2012–16
Table 13: Canada consumer price index (absolute), 2012–16
Table 14: Canada exchange rate, 2012–16
Table 15: Mexico generics market value: $ billion, 2012–16
Table 16: Mexico generics market volume: % of total pharma volume, 2012–16
Table 17: Mexico generics market geography segmentation: $ billion, 2016
Table 18: Mexico generics market value forecast: $ billion, 2016–21
Table 19: Mexico generics market volume forecast: % of total pharma volume, 2016–21
Table 20: Mexico size of population (million), 2012–16
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2012–16
Table 22: Mexico gdp (current prices, $ billion), 2012–16
Table 23: Mexico inflation, 2012–16
Table 24: Mexico consumer price index (absolute), 2012–16
Table 25: Mexico exchange rate, 2012–16
Table 26: United States generics market value: $ billion, 2012–16
Table 27: United States generics market volume: % of total pharma volume, 2012–16
Table 28: United States generics market geography segmentation: $ billion, 2016
Table 29: United States generics market value forecast: $ billion, 2016–21
Table 30: United States generics market volume forecast: % of total pharma volume, 2016–21
Table 31: United States size of population (million), 2012–16
Table 32: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 33: United States gdp (current prices, $ billion), 2012–16
Table 34: United States inflation, 2012–16
Table 35: United States consumer price index (absolute), 2012–16
Table 36: United States exchange rate, 2012–15
Table 37: Apotex, Inc.: key facts
Table 38: Mylan Inc.: key facts
Table 39: Mylan Inc.: key financials ($)
Table 40: Mylan Inc.: key financial ratios
Table 41: Sandoz International GmbH: key facts
Table 42: Teva Pharmaceutical Industries Limited: key facts
Table 43: Teva Pharmaceutical Industries Limited: key financials ($)
Table 44: Teva Pharmaceutical Industries Limited: key financial ratios
Table 45: Allergan plc: key facts
Table 46: Allergan plc: key financials ($)
Table 47: Allergan plc: key financial ratios
List of Figures
Figure 1: NAFTA countries generics industry, revenue ($bn), 2012-21
Figure 2: NAFTA countries generics industry, revenue ($bn), 2012-16
Figure 3: NAFTA countries generics industry forecast, revenue ($bn), 2016-21
Figure 4: Canada generics market value: $ billion, 2012–16
Figure 5: Canada generics market volume: % of total pharma volume, 2012–16
Figure 6: Canada generics market geography segmentation: % share, by value, 2016
Figure 7: Canada generics market value forecast: $ billion, 2016–21
Figure 8: Canada generics market volume forecast: % of total pharma volume, 2016–21
Figure 9: Forces driving competition in the generics market in Canada, 2016
Figure 10: Drivers of buyer power in the generics market in Canada, 2016
Figure 11: Drivers of supplier power in the generics market in Canada, 2016
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2016
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2016
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2016
Figure 15: Mexico generics market value: $ billion, 2012–16
Figure 16: Mexico generics market volume: % of total pharma volume, 2012–16
Figure 17: Mexico generics market geography segmentation: % share, by value, 2016
Figure 18: Mexico generics market value forecast: $ billion, 2016–21
Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2016–21
Figure 20: Forces driving competition in the generics market in Mexico, 2016
Figure 21: Drivers of buyer power in the generics market in Mexico, 2016
Figure 22: Drivers of supplier power in the generics market in Mexico, 2016
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2016
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2016
Figure 26: United States generics market value: $ billion, 2012–16
Figure 27: United States generics market volume: % of total pharma volume, 2012–16
Figure 28: United States generics market geography segmentation: % share, by value, 2016
Figure 29: United States generics market value forecast: $ billion, 2016–21
Figure 30: United States generics market volume forecast: % of total pharma volume, 2016–21
Figure 31: Forces driving competition in the generics market in the United States, 2016
Figure 32: Drivers of buyer power in the generics market in the United States, 2016
Figure 33: Drivers of supplier power in the generics market in the United States, 2016
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2016
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2016
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2016
Figure 37: Mylan Inc.: revenues & profitability
Figure 38: Mylan Inc.: assets & liabilities
Figure 39: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 40: Teva Pharmaceutical Industries Limited: assets & liabilities
Figure 41: Allergan plc: revenues & profitability
Figure 42: Allergan plc: assets & liabilities
